Clinical Trial Update: Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated sirolimus, tacrolimus, and antithymocyte globulin to prevent graft-versus-host disease in patients with hematologic cancers undergo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms
• Plasma Cell Neoplasm

Drugs mentioned

• Antithymocyte Globulin (anti-thymocyte globulin)
• Prograf (Tacrolimus) (Tacrolimus)
• Rapamune (sirolimus) (sirolimus)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Chronic Myeloproliferative Disorders, Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2017-06-28